People have increasing opportunities to participate in genetic testing that can indicate their range of risk for developing a disease. Receiving these results does not appreciably drive up or diminish test recipients’ demand for potentially costly follow-up health services, according to a study performed by researchers at the National Institutes of Health and colleagues at other institutions.

Statins, including Pfizer Inc.’s Lipitor, are among the most prescribed drug in the world, and are currently routinely taken by millions of Americans. They are indicated for people with high blood pressure and/or high cholesterol, and have been shown to significantly reduce the risk of heart disease, heart attack, and stroke in this population. Yet the FDA has just issued new warnings concerning potential side effects: elevated blood sugar, which is a risk factor for developing type 2 diabetes, and cognitive impairment such as memory loss. The warnings will not be affixed to the outside of the bottle, but will be included in the package insert that comes with all prescription medications.

According to a study in the February 15 edition of the Journal of Cardiovascular Electrophysiology, abnormal heart rate turbulence is associated with an increased risk of heart disease death in otherwise older, low-risk individuals [1]. Additional studies need to be done in order to understand whether this potential biomarker will be a clinically valuable tool.

Obstructive sleep apnea is associated with an increased risk of stroke in middle-aged and older adults, especially men, according to new results from a landmark study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Overall, sleep apnea more than doubles the risk of stroke in men. Obstructive sleep apnea is a common disorder in which the upper airway is intermittently narrowed or blocked, disrupting sleep and breathing during sleep.

High blood pressure or hypertension affects more than one in three people worldwide and is a major cause of strokes, heart attacks and heart failure [1]. The degree with which blood pressure traits can be inherited suggests a genetic component. However, limited consistent evidence of genes associated with blood pressure have been produced. A new study in the journal Nature Genetics reports for the first time a number of genes showing significant associations with blood pressure and hypertension across the genome [2].

Although large-scale genome-wide association studies (GWAS) have been used successfully to identify genes associated with common diseases and traits, studies on blood pressure or hypertension have failed to identify loci at a genome-wide significant threshold (p-value < 5 x 10^-8). The significance of GWAS data relies on several variables, including the accuracy of phenotypic measures, density of markers and size of the study population. Thus, if blood pressure variation in the general population is due to multiple genetic factors with small effects, a very large sample size is needed to identify them.